landscap
vaccin
manufactur
chang
radic
past
year
dozen
licens
vaccin
manufactur
oper
unit
state
alon
number
sinc
collaps
merger
exit
bare
hand
low
profit
margin
introduct
good
manufactur
practic
gmp
vaccin
product
caus
manufactur
cost
skyrocket
specter
liabil
contribut
contract
industri
five
companieschiron
emeryvil
ca
usa
glaxosmithklin
brentford
uk
merck
whitehous
station
nj
usa
sanofi
pasteur
lyon
franc
wyeth
madison
nj
usa
account
close
influenza
vaccin
suppli
world
fig
landscap
may
chang
attent
rivet
vaccin
suppli
anticip
possibl
influenza
pandem
price
vaccin
jump
dollar
cours
routin
pediatr
vaccin
wyeth
blockbust
vaccin
prevnar
pneumococc
conjug
vaccin
mening
bloodstream
infect
say
prevnar
transform
vaccin
busi
almost
overnight
although
vaccin
sale
whole
risen
rather
modestli
past
year
billion
billion
todaya
pittanc
compar
drug
market
wholerec
project
show
vaccin
market
grow
doubl
digit
annual
outpac
infecti
diseas
sector
new
crop
vaccin
like
merck
gardasil
recombin
vaccin
compris
human
papilloma
viru
hpv
subtyp
recent
shown
effect
prevent
cervic
cancer
project
bring
million
billion
annual
keep
demand
new
vaccin
let
alon
respond
possibl
epidem
natur
manmad
could
well
overwhelm
alreadi
stretchedtocapac
manufactur
prophylact
although
vaccin
manufactur
loath
discuss
capac
right
highli
politic
environ
creat
fear
influenza
pandem
look
activ
suggest
concern
capac
commit
increas
top
five
vaccineproduc
compani
increas
capac
either
acquisit
build
facil
scratch
tabl
flurri
big
pharma
merger
acquisit
activ
fall
center
target
larg
influenza
vaccin
franchis
underlin
extent
vaccin
consid
worthwhil
invest
opportun
industri
complianc
gmp
guidelin
previous
allow
deviat
view
isol
current
approach
holist
environ
everi
problem
need
look
qualiti
system
failur
influenza
vaccin
produc
come
increas
scrutini
debacl
chiron
fluvirin
trival
inactiv
influenza
viru
vaccin
product
plant
speke
england
last
year
begin
year
fda
increas
schedul
inspect
everi
two
year
annual
audit
current
consid
extend
regim
produc
medic
necessari
product
particularli
produc
offshor
accord
present
mari
malarkey
director
cber
offic
complianc
biolog
qualiti
annual
gmp
sea
confer
held
cambridg
maryland
august
although
five
big
player
domin
industri
present
hegemoni
challeng
innov
biotech
compani
work
creat
new
robust
deliveri
system
box
demonstr
recent
novarti
bid
within
peer
group
also
dynam
easili
explain
vaccin
market
enjoy
compound
annual
growth
rate
accord
john
savopoulo
head
infecti
diseas
team
londonbas
market
analyst
datamonitor
estim
global
revenu
rose
million
billion
time
doubledigit
sale
growth
set
continu
forese
futur
market
attract
mani
area
healthcar
offer
kind
growth
claim
precis
forecast
difficult
say
substanti
level
vaccin
purchas
driven
public
polici
recommend
whose
implement
alway
predict
nevertheless
sever
driver
propel
market
demand
influenza
vaccin
must
redesign
year
match
curent
strain
continu
rise
unit
state
atlantabas
center
diseas
control
prevent
cdc
healthi
peopl
initi
aim
boost
infecti
diseas
immun
vaccin
industri
big
player
less
open
innov
present
savopoulo
say
sector
went
phase
explor
weird
wonder
technolog
therapeut
vaccin
sometim
refer
pharmaccin
littl
success
prevnar
demonstr
commerci
feasibl
develop
product
less
technic
risk
big
guy
seem
quit
happi
day
say
savopoulo
even
cell
cultur
propos
one
potenti
improv
influenza
vaccin
product
may
make
much
impact
argu
still
limit
dirti
purif
process
current
use
eggbas
vaccin
thu
far
moreov
recombin
vaccin
produc
cell
appear
immunogen
eggbas
counterpart
research
crack
say
estim
cell
culturebas
influenza
virus
may
take
overal
market
histor
underinvest
vaccin
innov
combin
focu
big
five
player
largescal
product
franchis
provid
biotech
compani
plethora
nich
opportun
tabl
accord
alexand
von
galbain
ceo
viennabas
intercel
replac
current
approv
vaccin
produc
use
obscur
materi
repres
one
obviou
opportun
intercel
recent
move
lead
product
vaccin
japanes
enceph
viru
jev
infect
pivot
trial
intercel
candid
product
base
inactiv
viru
grown
tissu
cultur
contrast
vaccin
current
market
extract
brain
suckl
mice
say
caus
high
level
allerg
reaction
well
side
effect
acambi
cambridg
usa
target
jev
well
live
attenu
recombin
vaccin
base
chimer
yellow
fever
viral
vector
receiv
fda
approv
initi
pivot
trial
say
cso
thoma
monath
biotech
compani
matur
pipelin
vaccin
product
inevit
face
decis
manufacturingwheth
partner
exist
manufactur
outsourc
retain
product
exclus
via
contract
manufactur
organ
cmo
whether
develop
inhous
manufactur
capabl
howev
outsourc
might
answer
accord
peter
wulff
ceo
bavarian
nordic
kvistgaard
denmark
mani
cmo
either
ask
cash
upfront
pay
invest
need
product
depreci
cost
first
product
run
biotech
compani
carri
lot
cost
upfront
either
way
say
intercel
acquir
facil
livingston
scotland
bavarian
nordic
vy
acambi
win
larg
us
govern
contract
stockpil
safe
smallpox
vaccin
base
modifi
vaccinia
ankara
vector
also
acquir
product
facil
kvistgaard
denmark
orion
pharma
espoo
finland
us
project
bioshield
program
signific
sourc
recent
growth
us
author
spend
hundr
million
dollar
stockpil
protect
anthrax
smallpox
tabl
well
smaller
invest
new
product
develop
tabl
agent
recent
offradar
biotech
compani
repres
import
sourc
inject
dnabas
vaccin
receiv
doubl
boost
year
vaccin
infecti
hematopoiet
necrosi
viru
ihnv
farm
salmon
west
nile
viru
hors
gain
approv
canada
unit
state
respect
proofofconcept
first
demonstr
mice
decad
ago
initi
promis
meet
expect
similar
effect
seen
human
trial
although
accord
vijay
samant
ceo
san
diego
californiabas
dna
vaccin
specialist
vical
much
expect
technolog
quickli
peopl
ran
excit
technolog
appli
tough
target
say
moreov
merck
vical
partner
firm
actual
subject
technolog
efficaci
trial
sinc
nobodi
done
doubleblind
infecti
diseas
efficaci
trial
say
dna
vaccin
base
bacteri
plasmid
attract
option
precis
defin
easili
cultiv
recombin
bacteria
appear
safe
also
contain
cpg
motif
characterist
bacteri
dna
trigger
innat
immun
respons
aqua
health
charlottetown
princ
edward
island
canada
compani
gain
approv
salmon
vaccin
vical
license
harlow
ukbas
merial
anim
health
joint
ventur
sanofiaventi
merck
aim
gain
approv
canin
melanoma
vaccin
next
year
three
weight
categori
small
medium
larg
anim
valid
technolog
samant
say
deliveri
suffici
quantiti
dna
elicit
strong
immun
respons
biggest
obstacl
progress
sever
avenu
explor
vical
use
adjuv
base
cation
lipid
provid
degre
physic
protect
dna
encount
cell
membran
hightech
method
also
develop
powderm
spun
chiron
last
year
continu
develop
needlefre
dna
vaccin
deliveri
method
latter
gain
purchas
oxford
ukbas
firm
powderject
version
technolog
call
particlemedi
epiderm
deliveri
around
decad
reli
use
tini
gold
particl
carrier
plasmid
dna
propel
nearsuperson
speed
pressur
helium
ga
penetr
antigenpres
dendrit
cell
keratinocyt
beneath
surfac
skin
insid
cell
plasmid
dna
elut
particl
becom
transcript
activ
ceo
clive
dix
join
powderject
glaxosmithklin
say
technolog
overcom
deliveri
problem
hamper
progress
dna
vaccin
human
requir
one
two
microgram
dna
elicit
respons
peopl
talk
us
slightli
skeptic
still
say
dix
say
approach
could
offer
rapid
novel
approach
manufactur
build
factori
would
capac
produc
million
dose
vaccin
three
month
date
somebodi
say
vaccin
produc
powderm
plan
move
lead
project
vaccin
pandem
influenza
human
trial
next
year
intramuscular
electropor
also
gain
ground
acquisit
earlier
year
norwegian
pioneer
area
inovio
genetron
biomed
merg
entiti
inovio
biomed
san
diego
focus
oncolog
licens
dna
vaccin
applic
partner
includ
chiron
vical
chiron
jeffrey
ulmer
say
increas
effici
dna
taken
target
cell
although
technolog
still
prove
term
safeti
toler
practic
powderm
technolog
manufactur
dispos
devic
one
would
imagin
technolog
develop
one
could
appli
principl
electropor
say
ulmer
revenu
well
r
fund
firm
vaxgen
brisban
ca
acambi
bavarian
nordic
overal
market
still
rel
small
individu
product
success
substanti
impact
toplin
wyeth
prevnar
pediatr
vaccin
caus
agent
invas
pneumococc
diseas
streptococcu
pneumonia
repres
major
technolog
breakthrough
savopoulo
say
contain
saccharid
deriv
capsular
antigen
seven
common
pneumonia
serotyp
individu
conjug
nontox
variant
highli
immunogen
diphtheria
toxin
isol
corynebacterium
diphtheria
strain
yet
repres
kind
commerci
breakthrough
valid
broader
vaccin
space
first
approv
fda
februari
clock
revenu
applic
file
product
gardasil
protect
two
hpv
strain
implic
cervic
cancer
two
implic
develop
genit
wart
immin
sanofi
pasteur
msd
european
joint
ventur
sanofi
pasteur
due
file
europ
shortli
afterward
glaxosmithklin
develop
rival
product
cervarix
collabor
medimmun
gaithersburg
md
usa
aim
file
europ
yet
disclos
time
frame
us
file
although
merck
may
first
market
product
codevelop
csl
parkevil
australia
glaxosmithklin
stand
gain
royalti
stream
franchis
well
follow
settlement
patent
disput
two
compani
earlier
year
vaccin
repres
import
element
glaxosmithklin
growth
strategi
uncharacterist
main
focu
pipelin
updat
summer
